On July 8, Moderna fell 5.04% in regular trading, trading at $76.05/share, with turnover of $60.01 million. The decline extends a pullback that began as institutional bearish sentiment collided with profit-taking pressure following a significant rally.

On the news front, Bank of America raised its price target on Moderna from $34 to $38 but maintained its Underperform rating. The revised target still implies more than 50% downside from the current stock price and remains well below the FactSet consensus target of $50.53. Additionally, BofA noted that Moderna's upcoming Q2 results may face increased scrutiny given its year-to-date outperformance in ongoing drug launches.

Moderna had surged over 18% in the prior week, driven by its seasonal flu vaccine candidate mRNA-1010 receiving unanimous 9-0 support from an FDA advisory committee, with a final approval decision expected by August 5. Market participants widely regard these catalysts as fully priced in. The combination of a clear institutional bearish stance and sustained profit-taking continues to pressure the stock lower.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)